AMSBIO launches ready-to-use hiPSC-derived cells for medical research

AMSBIO launches ready-to-use hiPSC-derived cells for medical research

AMSBIO introduces pre-differentiated human induced Pluripotent Stem Cell (hiPSC)-derived cells, offering researchers fully functional cardiomyocytes, hepatocytes and neurons without time-consuming in-house differentiation procedures, potentially transforming research workflows and accelerating discovery timelines.

GeneDx unveils ultrarapid whole genome sequencing for critical paediatric care

GeneDx has unveiled an ultrarapid whole genome sequencing service delivering diagnostic results for critically ill neonatal and paediatric patients within 48 hours. This technological advancement could potentially generate healthcare savings exceeding $15,000 per child while significantly enhancing clinical outcomes through earlier intervention.

Testa Analytical

Testa Analytical unveils breakthrough in molecular weight determination precision

Testa Analytical has released a differential refractometer that promises to significantly improve the accuracy of molecular weight determination in biopolymers and polymers. The instrument, designed specifically as an accessory for light scattering equipment, addresses one of the fundamental challenges in molecular characterisation: obtaining precise specific refractive index increment (dn/dc) values.

mimetas

MIMETAS unveils breakthrough in flow system technology for disease modelling

MIMETAS has introduced OrganoPlate UniFlow (UF), the first commercial platform offering unidirectional, gravity-driven pumpless flow systems for disease research. This innovation significantly advances tissue model development for pharmaceutical research by replicating physiological conditions without complex equipment.

CN Bio DILI Kit

CN Bio releases new in vitro DILI assay kit for toxicology screening

CN Bio has launched an all-in-one drug-induced liver injury (DILI) testing kit that enables pharmaceutical researchers to conduct in-house hepatotoxicity screening using organ-on-chip technology. The system provides human-relevant data to support more informed candidate selection during preclinical development.

EDX Medical

Edx Medical pioneers multi-biomarker testing approach for prostate cancer detection

Cambridge scientists at EDX Medical Group have developed an innovative diagnostic test for prostate cancer that combines over 100 biomarkers with AI analysis, potentially transforming screening accuracy with sensitivity and specificity rates between 96-99%.

Professor Bo Wang, Senior Advisor, Shift Bioscience

AI-powered virtual cell platform expands as Shift Bioscience establishes Toronto base

The Cambridge-based biotech company Shift Bioscience has announced the establishment of new facilities in Toronto, Canada, marking a strategic expansion of their AI capabilities in the development of virtual cell technology. The move follows their recent $16M seed funding round and positions the company to tap into North America’s rich pool of artificial intelligence talent.

artificial digital twin

Artificial integrates NVIDIA’s BioNeMo to advance AI-driven drug discovery workflows

Artificial Inc has successfully demonstrated the integration of NVIDIA’s BioNeMo generative AI platform with its laboratory orchestration system, showcasing capabilities for self-driving virtual screening in drug discovery applications. The proof-of-concept represents a significant technical advancement in applying AI technologies to pharmaceutical research workflows.

Mike Hampton, Rob Brown

Sapio Sciences bolsters leadership team to accelerate AI-driven lab informatics evolution

Sapio Sciences has announced significant leadership changes designed to strengthen its position in the AI-driven lab informatics sector. The Baltimore-based company, known for its “science-aware” platform, has appointed Mike Hampton as Chief Commercial Officer while simultaneously establishing a dedicated Scientific Office to enhance its research and development capabilities.

BioMerieux logo

Ten-minute cardiac diagnostics: bioMérieux’s strategic acquisition targets emergency care transformation

bioMérieux has announced the acquisition of SpinChip Diagnostics ASA, a privately held Norwegian company specialising in rapid immunoassay diagnostics. The €138 million deal will see bioMérieux acquire 100% ownership of the company, with a cash outlay of approximately €111 million, accounting for the 20% minority stake bioMérieux has held since March 2024.